Abstract
In this study, we developed a subcutaneous insulin-releasing device consisting of a disk-shaped capsule and drug formulation comprised of poly(ethylene glycol) dimethacrylates, then evaluated its efficacy on retinal function in streptozotocin (STZ)-induced diabetic rats. In vitro release studies showed that recombinant human insulin was released with a constant rate for more than 30 days. The device was able to maintain a basal level of blood glucose in diabetic rats for a prolonged period of more than 30 days, simultaneously preventing a decrease in body weight. For assessing the pharmacological effect of the device on retinal function in diabetic rats, electroretinograms were conducted for 12 weeks. The reduction in amplitude and delay in implicit time were attenuated by the device during the initial 4 weeks of application. The increase in gene expression of protein kinase C (PKC)-γ and caspase-3 in the diabetic retina was also attenuated by the device. Immunohistochemistry showed that the increase in glial fibrillary acidic protein expression in the diabetic retina was attenuated by the device. Histological evaluation of subcutaneous tissue around the device showed the biocompatibility of the device. In conclusion, the insulin-releasing device attenuated the reduction of retinal function in STZ-induced diabetic conditions for 4 weeks and the efficacy of the device might be partially related to PKC signaling in the retina. The long-term ability to control the blood glucose level might help to reduce the daily frequency of insulin injections.
Similar content being viewed by others
References
Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124–36.
Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.
Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res. 1998;37:586–600.
Arnal E, Miranda M, Johnsen-Soriano S, Alvarez-Nolting R, Diaz-Llopis M, Araiz J, et al. Beneficial effect of docosahexanoic acid and lutein on retinal structural, metabolic, and functional abnormalities in diabetic rats. Curr Eye Res. 2009;34:928–38.
Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes. 1998;47:859–66.
Reiter CE, Wu X, Sandirasegarane L, Nakamura M, Gilbert KA, Singh RS, et al. Diabetes reduces basal retinal insulin receptor signaling: reversal with systemic and local insulin. Diabetes. 2006;55:1148–56.
Aiello LP. Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:17–23.
Khan MI, Barlow RB, Weinstock RS. Acute hypoglycemia decreases central retinal function in the human eye. Vis Res. 2011;51:1623–6.
Wong CY, Al-Salami H, Dass CR. Recent advancements in oral administration of insulin-loaded liposomal drug delivery systems for diabetes mellitus. Int J Pharm. 2018;549:201–17.
Vasconcelos Silva EL, Oliveira ACJ, Patriota YBG, Ribeiro AJ, Veiga F, Hallwass F, et al. Solvent-free synthesis of acetylated cashew gum for oral delivery system of insulin. Carbohydr Polym. 2019;207:601–8.
Schmid V, Kullmann S, Gfrorer W, Hund V, Hallschmid M, Lipp HP, et al. Safety of intranasal human insulin: a review. Diabetes Obes Metab. 2018;20:1563–77.
Chono S, Togami K, Itagaki S. Aerosolized liposomes with dipalmitoyl phosphatidylcholine enhance pulmonary absorption of encapsulated insulin compared with co-administered insulin. Drug Dev Ind Pharm. 2017;43:1892–8.
Li H, Zhang Z, Bao X, Xu G, Yao P. Fatty acid and quaternary ammonium modified chitosan nanoparticles for insulin delivery. Colloids Surf B Biointerfaces. 2018;170:136–43.
Ansary RH, Rahman MM, Awang MB, Katas H, Hadi H, Doolaanea AA. Preparation, characterization, and in vitro release studies of insulin-loaded double-walled poly(lactide-co-glycolide) microspheres. Drug Deliv Transl Res. 2016;6:308–18.
Zhao F, Wu D, Yao D, Guo R, Wang W, Dong A, et al. An injectable particle-hydrogel hybrid system for glucose-regulatory insulin delivery. Acta Biomater. 2017;64:334–45.
Misra GP, Singh RS, Aleman TS, Jacobson SG, Gardner TW, Lowe TL. Subconjunctivally implantable hydrogels with degradable and thermoresponsive properties for sustained release of insulin to the retina. Biomaterials. 2009;30:6541–7.
Peng Q, Yang YJ, Zhang T, Wu CY, Yang Q, Sun X, et al. The implantable and biodegradable PHBHHx 3D scaffolds loaded with protein-phospholipid complex for sustained delivery of proteins. Pharm Res. 2013;30:1077–85.
Yamada S, Nagai N, Saijo S, Kaji H, Nishizawa M, Imura K, et al. Controlled basic fibroblast growth factor release device made of poly(ethylene glycol) dimethacrylates for creating a subcutaneous neovascular bed for cell transplantation. J Biomed Mater Res A. 2017;105:3017–24.
Nagai N, Kaji H, Nishizawa M, Nakazawa T, Abe T. Transscleral controlled delivery of geranylgeranylaceton using a polymeric device protects rat retina against light injury. Adv Exp Med Biol. 2016;854:471–7.
Nagai N, Kaji H, Onami H, Ishikawa Y, Nishizawa M, Osumi N, et al. A polymeric device for controlled transscleral multi-drug delivery to the posterior segment of the eye. Acta Biomater. 2014;10:680–7.
Kawashima T, Nagai N, Kaji H, Kumasaka N, Onami H, Ishikawa Y, et al. A scalable controlled-release device for transscleral drug delivery to the retina. Biomaterials. 2011;32:1950–6.
Nagai N, Koyanagi E, Izumida Y, Liu J, Katsuyama A, Kaji H, et al. Long-term protection of genetically ablated rabbit retinal degeneration by sustained transscleral unoprostone delivery. Invest Ophthalmol Vis Sci. 2016;57:6527–38.
P V J, Nair SV, Kamalasanan K. Current trend in drug delivery considerations for subcutaneous insulin depots to treat diabetes. Colloids Surf B Biointerfaces. 2017;153:123–31.
Li Q, Zemel E, Miller B, Perlman I. Early retinal damage in experimental diabetes: electroretinographical and morphological observations. Exp Eye Res. 2002;74:615–25.
Rong X, Ji Y, Zhu X, Yang J, Qian D, Mo X, et al. Neuroprotective effect of insulin-loaded chitosan nanoparticles/PLGA-PEG-PLGA hydrogel on diabetic retinopathy in rats. Int J Nanomed. 2019;14:45–55.
Kang N, Alexander G, Park JK, Maasch C, Buchwalow I, Luft FC, et al. Differential expression of protein kinase C isoforms in streptozotocin-induced diabetic rats. Kidney Int. 1999;56:1737–50.
Suryavanshi SV, Kulkarni YA. NF-kappabeta: a potential target in the management of vascular complications of diabetes. Front Pharm. 2017;8:798.
Stitt A, Gardiner TA, Alderson NL, Canning P, Frizzell N, Duffy N, et al. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes. 2002;51:2826–32.
Hammes HP, Alt A, Niwa T, Clausen JT, Bretzel RG, Brownlee M, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia. 1999;42:728–36.
Aung MH, Kim MK, Olson DE, Thule PM, Pardue MT. Early visual deficits in streptozotocin-induced diabetic long evans rats. Invest Ophthalmol Vis Sci. 2013;54:1370–7.
Nagai N, Saijo S, Song Y, Kaji H, Abe T. A drug refillable device for transscleral sustained drug delivery to the retina. Eur J Pharm Biopharm. 2019;136:184–91.
Acknowledgements
This study was supported by a Basic Science and Platform Technology Program for Innovative Biological Medicine, from the Japan Agency for Medical Research and Development (AMED), Japan, and the Business Incubation Program (BIP), from Tohoku University, Japan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Hoshi, A., Nagai, N., Daigaku, R. et al. Effect of sustained insulin-releasing device made of poly(ethylene glycol) dimethacrylates on retinal function in streptozotocin-induced diabetic rats. J Mater Sci: Mater Med 31, 52 (2020). https://doi.org/10.1007/s10856-020-06392-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s10856-020-06392-8